Why this type of language isn’t helpful, and success still depends on support.

Key points

• GLP-1s reduce hunger and “food noise,” creating space for healthier relationships with food.
• Moralised narratives about the “easy way out” ignore the complex reasons people live in larger bodies.
• Friends, families, and clinicians reduce harm by focusing on support and well-being, not judgment or blame.

New glucagon-like peptide-1 (GLP‑1) weight‑management medications such as Mounjaro and Wegovy represent a major shift in obesity treatment. In the United States, recent survey data suggest that about one in eight adults has taken a GLP‑1 medication, and around 6 percent are currently using one.[1] In the United Kingdom, it is estimated that nearly one in 10 adults have either recently used or are actively interested in these drugs.[2]

These medications are highly effective. Large studies of GLP-1 use show average weight losses of around 10 to 22 percent of initial body weight over 1 to 1.5 years, with many losing 20 percent or more.[3] Lots describe the impact as life‑changing. At the same time, the rapid rise in GLP‑1 use has triggered intense public, clinical, and media debate. Alongside enthusiasm, we have started to see stigmatising narratives about what it means to take these drugs.

"Cheating" and the "easy way out"

Early evidence suggests that some people using GLP‑1s experience negative attitudes from others about their GLP-1 use. Examples include being told they are taking the "easy way out" or "cheating," echoing historic narratives around weight loss surgery.[4]

Studies show that people who lose weight with GLP‑1s are seen more negatively than those who lose weight via diet and exercise, and in some cases even more negatively than people who remain at a higher weight.[5] Research I’m currently conducting is suggesting that fears of such reactions lead to some users hiding their medication use from friends and family.

Weight is more than willpower

These statements ignore what we know about how complex body weight is. While diet and exercise matter, obesity is also shaped by our genetics, hormones, sleep, medications, trauma, mental health, and the environments we live in. As a result, many find it very hard to lose weight and keep it off. Behavioural weight‑loss programmes typically only achieve small losses, and weight regain over time is common.

GLP‑1 medications work mostly by reducing hunger, cravings, and so‑called "food noise." This helps people to feel fuller sooner and think about food less. Because of this, they are best thought of as a tool that can help people to develop better, healthier eating patterns and relationships with food. This does not remove the need for effort; it changes what that effort has to fight against.

The idea that GLP‑1s are the easy option and that anyone using them has somehow failed at traditional behavioural methods is therefore misleading. Data show that when these medications are stopped, people quickly regain weight.[6] For GLP‑1s to be effective in the long term, people typically need added support with their habits, thoughts and feelings about food, and body weight. All of that takes work.

article continues after advertisement

GLP‑1s do not represent a shortcut or moral failure; they are evidence‑based treatments for a complex long-term condition—treatments that can make change possible. The real ethical challenge is not whether individuals deserve to use them, but how we ensure access is safe, fair, and provided with the right kind of support.

Supporting people taking GLP-1s

Seeing GLP‑1s as legitimate treatment means our language and reactions matter. Non‑stigmatising support involves avoiding phrases like "easy way out" or "cheating" and instead acknowledging that people are making informed decisions about a long-term condition. It means respecting privacy, asking what support (if any) someone wants, and not policing their weight or food choices.

https://www.psychologytoday.com/gb/blog/surrey-minds/202606/are-glp-1s-really-the-easy-way-out